NRCNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
NRC HEALTH
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$20.47+0.32 (+1.59%)
Close on Oct 19, 2026
- Market cap
- $450.52M
- P/E (TTM)
- 0.4
- Dividend yield
- 2.54%
Margins
Share of revenue, fiscal years 2011 to 2025
Operating margin
16.4%−15.6 pts over 5 years
Net margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -4.0% | -3.2% | +0.6% | +3.0% | |
| Operating income | -35.8% | -21.4% | -11.9% | -1.6% | |
| EPS, diluted | +4707.7% | +240.2% | +103.0% | – | |
| Free cash flow | -17.9% | -15.9% | -15.5% | -1.8% | |
| Dividend per share | +8.3% | -14.8% | +19.9% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 26.1% | – | – | |
| Return on assets | 16.5% | – | – | |
| Current ratio | 1.49 | 1.71 | 0.55 | |
| Debt to equity | 0.04 | 0.41 | 5.65 | |
| Net debt to EBITDA | -0.83× | – | 2.48× | |
| Interest coverage | 164.2× | 23.5× | 4.7× | |
| Capex to revenue | 3.6% | 3.0% | 7.8% | |
| Diluted shares | – | 26M | 22M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Nrc Health generated $181.80M from operations and spent $248.18M on capital expenditure, dividends and share buybacks. 23% of that went back into the business.
Generated
$181.80M
Used
$248.18M
Capital expenditure$57.28M23%Dividends$88.92M36%Share buybacks$101.98M41%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin25.1%
×Asset turnover1.02×
×Equity multiplier2.16×
=Return on equity, FY201855.1%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2018 | 25.1% | 1.02× | 2.16× | 55.1% |
| FY2017 | 19.5% | 0.95× | 1.43× | 26.5% |
| FY2016 | 18.8% | 0.88× | 1.58× | 26.1% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 5 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero–
- Cash generatingOperating cash flow above zero$26.45M
- Return on assets improvedROA up on the prior year– → –
- Earnings backed by cashOperating cash flow above net income$26.45M vs –
- Less leverageLong-term debt to assets fell43.7% → 55.6%
- Better liquidityCurrent ratio rose0.55 → 0.55
- No dilutionShare count did not rise24M → 22M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose1.17 → 1.04